Table 4.

Minimum inhibitory concentrations of erythromycin and clindamycin resistant isolates, D-shape and screened genes (n = 29)

No	MIC (µg/ml)		D-shape	MLS	Genes
	Erythromycin	Clindamycin
1	1 (R)	0.50 (I)	Negative	cMLSB	ermB
2	3 (R)	0.75 (I)	Negative	cMLSB	linB + ermB
3	0.75 (I)	0.75 (I)	Negative	cMLSB	linB + ermB
4	0.50 (I)	0.047 (S)	Negative	M phenotype	mefA
5	0.75 (I)	1 (R)	Negative	cMLSB	ermB
6	4 (R)	0.50 (I)	Negative	cMLSB	ermB
7	1 (R)	0.38 (I)	Negative	cMLSB	ermB
8	0.75 (I)	1 (R)	Negative	cMLSB	ermB
9	0.75 (I)	4 (R)	Negative	cMLSB	linB + ermB
10	4 (R)	7 (R)	Negative	cMLSB	ermB
11	2 (R)	0.047 (S)	Positive	iMLSB	ermTR
12	1.5 (R)	0.016 (S)	Positive	iMLSB	ermB
13	0.75 (I)	0.50 (I)	Negative	cMLSB	linB + ermB
14	8 (R)	0.38 (I)	Negative	cMLSB	ermB
15	0.25 (S)	2 (R)	Negative	L phenotype	linB + ermB
16	8 (R)	1 (R)	Negative	cMLSB	linB + ermB
17	0.75 (I)	1 (R)	Negative	cMLSB	ermB
18	3 (R)	0.38 (I)	Negative	cMLSB	ermB
19	1 (R)	0.38 (I)	Negative	cMLSB	ermB
20	1.5 (R)	0.25 (S)	Positive	iMLSB	ermB
21	0.25 (S)	1 (R)	Negative	L phenotype	linB + ermB
22	3 (R)	0.047 (S)	Positive	iMLSB	ermB
23	0.50 (I)	0.75 (I)	Negative	cMLSB	linB + ermB
24	2 (R)	8 (R)	Negative	cMLSB	ermB
25	0.75 (I)	0.50 (I)	Negative	cMLSB	linB + ermB
26	0.75 (I)	0.094 (S)	Negative	M phenotype	ermB
27	4 (R)	0.023 (S)	Positive	iMLSB	ermB
28	0.50 (I)	1 (R)	Negative	cMLSB	linB + ermB
29	0.75 (I)	0.50 (I)	Negative	cMLSB	linB + ermB

S susceptible, R resistant, I intermediate, cMLS _B MLS_B-constitutive methylation [erythro (R), clinda (R)], iMLS _B MLS_B-inducible methylation [erythro (R), clinda (S) with blunting], M-phenotype efflux pump mechanism [erythro (R), clinda (S) without blunting], L-phenotype erythro (S), clinda (R)